Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5521186 | 1.00 | CYSLTR2 (0.58) | CYSLTR2CYSLTR1 | |
| SCHEMBL3234021 | 0.97 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1 | |
| SCHEMBL5694750 | 0.97 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1 | |
| SCHEMBL524722 | 0.92 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1 | |
| SCHEMBL20490657 | 0.92 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1 | |
| SCHEMBL5521192 | 0.92 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1 | |
| SCHEMBL589317 | 0.85 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1 | |
| SCHEMBL209124 | 0.85 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1 | |
| SCHEMBL5971548 | 0.85 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1 | |
| SCHEMBL227362 | 0.85 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3925607-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-3436446-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3925607-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210308053-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3424534-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10980746-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-04-20 | — | — | US | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| WO-2008049875-A1 | NOVEL SUBSTITUTED PIPERIDYL-PROPANE-THIOLS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-02 | — | — | WO | disclosed |
| US-20070282276-A1 | PROCESS AND DEVICE FOR DOSING PHARMACEUTICAL AGENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-12-06 | — | — | US | disclosed |
| US-20070259846-A1 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070240714-A1 | DISPENSING DEVICE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070163574-A1 | DISPENSING DEVICE, STORAGE DEVICE AND METHOD FOR DISPENSING A FORMULATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070154407-A1 | INHALER AND STORE FOR A DRY MEDICAMENT FORMULATION AND RELATED METHODS AND USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-05 | — | — | US | disclosed |
| WO-2007051536-A1 | METHOD AND DEVICE FOR METERING MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2007-05-10 | — | — | WO | disclosed |
| US-20060258861-A1 | Respiratory or gastrointestinal disorders; cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
| US-20060247230-A1 | Novel Piperidine-Substituted Indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-02 | — | — | US | disclosed |
| US-20060134007-A1 | Blister for inhalers | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258861-A1 | Respiratory or gastrointestinal disorders; cancer | CYP2E1, UGT1A1, SLC26A4 | CYSLTR2 488/4885CYSLTR1 204/4885 |
| US-20210308053-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | CFTR, SLC26A4, PKD1 | CYSLTR2 334/4885CYSLTR1 197/4885 |
| US-10980746-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | CYSLTR2 334/4885CYSLTR1 197/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | CYSLTR2 39/4885CYSLTR1 25/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CYSLTR2 265/4885CYSLTR1 166/4885 |
| US-20060247230-A1 | Novel Piperidine-Substituted Indoles | CCR3, CCR1, CCR2 | CYSLTR2 250/4885CYSLTR1 130/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | CYSLTR2 334/4885CYSLTR1 197/4885 |
| US-20070259846-A1 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | DPYD, DHODH, DPM1 | CYSLTR2 992/4885CYSLTR1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.